SCHEMBL2862707

SCHEMBL2862707

COCCNCCN(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
PRMT3 O60678 1/20 0.42
CARM1 Q86X55 1/20 0.42
PRMT6 Q96LA8 1/20 0.42
PRMT1 Q99873 1/20 0.42
PRMT8 Q9NR22 1/20 0.42
ANPEP P15144 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
KDM4E B2RXH2 4/20 0.35
SIGMAR1 Q99720 1/20 0.35
RECQL P46063 1/20 0.35
ADRB2 P07550 1/20 0.34
ALDH1A1 P00352 5/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PIK3CD O00329 1/20 0.33
PKM P14618 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.32
CA1 P00915 2/20 0.32
CA2 P00918 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2859138 0.86 CYP2C19 (0.54) CYP2C9CYP2C19PRMT3CARM1PRMT6
SCHEMBL2863159 0.86 TDP1 (0.56) CYP2C9CYP2C19PRMT3CARM1PRMT6
SCHEMBL11119 0.81
SCHEMBL344526 0.81 CYP2C9 (0.72) CYP2C9CYP2C19PRMT3CARM1PRMT6
SCHEMBL24603130 0.79 KDM4E (0.36) CYP2C9CYP2C19KDM4ERECQLADRB2
SCHEMBL18160820 0.78 CYP2C9 (0.50) CYP2C9CYP2C19PRMT3CARM1PRMT6
SCHEMBL3631301 0.78 KDM4E (0.42) CYP2C19KDM4ERECQLADRB2ALDH1A1
SCHEMBL7790112 0.78 KDM4E (0.42) CYP2C19KDM4ERECQLADRB2ALDH1A1
Hydrochloric Acid SCHEMBL2532416 0.78 L3MBTL1 (0.43) TDP1KDM4ERECQLADRB2ALDH1A1
Iodide SCHEMBL1835511 0.78 KDM4E (0.42) CYP2C19KDM4ERECQLADRB2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024232564-A1 STRONTIUM COMPOUND, METHOD FOR PRODUCING SAME, AND METHOD FOR FORMING THIN FILM USING SAME 한국화학연구원 2024-11-14 WO disclosed
US-11655262-B2 Process for the generation of metal-containing films BASF SE (DE) 2023-05-23 US disclosed
CN-111727272-B Method for producing metal-containing films 巴斯夫欧洲公司 2023-04-28 CN disclosed
US-20220220131-A1 PROCESS FOR THE GENERATION OF METAL-CONTAINING FILMS BASF SE (DE) 2022-07-14 US disclosed
US-11319332-B2 Process for the generation of metal-containing films BASF SE (DE) 2022-05-03 US disclosed
EP-3957769-A1 PROCESS FOR THE GENERATION OF METAL-CONTAINING FILMS BASF SE (DE) 2022-02-23 EP disclosed
EP-3728688-B1 PROCESS FOR THE GENERATION OF METAL-CONTAINING FILMS BASF SE (DE) 2021-11-10 EP disclosed
US-20210079520-A1 PROCESS FOR THE GENERATION OF METAL-CONTAINING FILMS WAYNE STATE UNIVERSITY (US) 2021-03-18 US disclosed
EP-3728688-A1 PROCESS FOR THE GENERATION OF METAL-CONTAINING FILMS BASF SE (DE) 2020-10-28 EP disclosed
CN-111727272-A Method for producing metal-containing film 巴斯夫欧洲公司 2020-09-29 CN disclosed
US-20090048223-A1 Sulfonamide compound ASAHI KASEI PHARMA CORPORATION (JP) 2009-02-19 US disclosed
US-20090048223-A1 Sulfonamide compound ASAHI KASEI PHARMA CORPORATION (JP) 2009-02-19 US disclosed
CN-101111483-A IGF-1R inhibitors KYOWA HAKKO KOGYO KK (JP) 2008-01-23 CN disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed
US-20070032532-A1 Hsp90 family protein inhibitors KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-02-08 US disclosed
EP-1642880-A1 HSP90 FAMILY PROTEIN INHIBITORS KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-04-05 EP disclosed
EP-0134019-B1 PROCESS FOR THE PREPARATION OF SELF-CURABLE RESINS AND THEIR USE BASF Lacke + Farben AG (DE) 1987-07-08 EP disclosed
US-4599371-A CATIONIC POLYMERS FOR ELECTROCOATINGS BASF AKTIENGESELLSCHAFT (DE) 1986-07-08 US disclosed
EP-0134019-A2 Process for the preparation of self-curable resins and their use BASF Lacke + Farben AG (DE) 1985-03-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220220131-A1 PROCESS FOR THE GENERATION OF METAL-CONTAINING FILMS NR4A2, NR2C2, NR2E1 CYP2C9 1756/4885CYP2C19 2016/4885PRMT3 300/4885
US-11655262-B2 Process for the generation of metal-containing films NR4A2, NR2C2, NR2E1 CYP2C9 1756/4885CYP2C19 2016/4885PRMT3 300/4885
US-20070032532-A1 Hsp90 family protein inhibitors HSP90AB1, HSP90B1, HSP90AB2P CYP2C9 1162/4885CYP2C19 1259/4885PRMT3 3196/4885
US-20210079520-A1 PROCESS FOR THE GENERATION OF METAL-CONTAINING FILMS NR4A2, NR3C2, NR2C2 CYP2C9 1947/4885CYP2C19 2351/4885PRMT3 277/4885
US-20090048223-A1 Sulfonamide compound ALK, AKT1, ARAF CYP2C9 1572/4885CYP2C19 1798/4885PRMT3 190/4885
US-11319332-B2 Process for the generation of metal-containing films NR4A2, NR2C2, NR2E1 CYP2C9 1756/4885CYP2C19 2016/4885PRMT3 300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.